Innoviva, Inc. (INVA)
21.06
+0.12
(+0.60%)
USD |
NASDAQ |
Oct 28, 15:56
Innoviva Enterprise Value : 1.212B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 1.212B |
| October 26, 2026 | 1.220B |
| October 23, 2026 | 1.191B |
| October 22, 2026 | 1.220B |
| October 21, 2026 | 1.209B |
| October 20, 2026 | 1.236B |
| October 19, 2026 | 1.222B |
| October 16, 2026 | 1.200B |
| October 15, 2026 | 1.206B |
| October 14, 2026 | 1.214B |
| October 13, 2026 | 1.197B |
| October 12, 2026 | 1.249B |
| October 09, 2026 | 1.231B |
| October 08, 2026 | 1.207B |
| October 07, 2026 | 1.220B |
| October 06, 2026 | 1.204B |
| October 05, 2026 | 1.190B |
| October 02, 2026 | 1.180B |
| October 01, 2026 | 1.183B |
| September 30, 2026 | 1.231B |
| September 29, 2026 | 1.224B |
| September 28, 2026 | 1.233B |
| September 25, 2026 | 1.197B |
| September 24, 2026 | 1.191B |
| September 23, 2026 | 1.161B |
| Date | Value |
|---|---|
| September 22, 2026 | 1.215B |
| September 21, 2026 | 1.219B |
| September 18, 2026 | 1.226B |
| September 17, 2026 | 1.220B |
| September 16, 2026 | 1.231B |
| September 15, 2026 | 1.204B |
| September 14, 2026 | 1.209B |
| September 11, 2026 | 1.191B |
| September 10, 2026 | 1.188B |
| September 09, 2026 | 1.225B |
| September 08, 2026 | 1.241B |
| September 04, 2026 | 1.240B |
| September 03, 2026 | 1.241B |
| September 02, 2026 | 1.241B |
| September 01, 2026 | 1.222B |
| August 31, 2026 | 1.199B |
| August 28, 2026 | 1.214B |
| August 27, 2026 | 1.213B |
| August 26, 2026 | 1.233B |
| August 25, 2026 | 1.228B |
| August 24, 2026 | 1.218B |
| August 21, 2026 | 1.221B |
| August 20, 2026 | 1.216B |
| August 19, 2026 | 1.251B |
| August 18, 2026 | 1.234B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 396.88B |
| Zevra Therapeutics, Inc. | 376.61M |
| ANI Pharmaceuticals, Inc. | 1.870B |
| Corcept Therapeutics, Inc. | 9.154B |
| Veru, Inc. | 15.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -83.42M |
| Revenue (Quarterly) | 123.05M |
| Total Expenses (Quarterly) | 206.47M |
| EPS Diluted (Quarterly) | -1.136 |
| Gross Profit Margin (Quarterly) | 73.64% |
| Profit Margin (Quarterly) | -67.80% |
| Earnings Yield | 19.49% |
| Operating Earnings Yield | 9.40% |
| Normalized Earnings Yield | 10.85 |